WENDELL DAVID ASSOCIATES INC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
WENDELL DAVID ASSOCIATES INC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$313
-16.5%
4,6000.0%0.04%
-11.9%
Q2 2023$375
+10.0%
4,6000.0%0.04%
+5.0%
Q1 2023$341
-10.5%
4,6000.0%0.04%
-14.9%
Q4 2022$381
-99.9%
4,600
+300.0%
0.05%
+6.8%
Q3 2022$327,000
-24.5%
1,150
-8.0%
0.04%
-20.0%
Q2 2022$433,000
-20.0%
1,2500.0%0.06%
-8.3%
Q1 2022$541,000
-16.4%
1,2500.0%0.06%
-7.7%
Q4 2021$647,000
+6.8%
1,2500.0%0.06%
-4.4%
Q3 2021$606,000
-0.3%
1,250
-7.4%
0.07%0.0%
Q2 2021$608,000
+6.1%
1,350
-10.0%
0.07%
-1.4%
Q1 2021$573,000
+20.4%
1,5000.0%0.07%
+19.0%
Q4 2020$476,000
+28.0%
1,5000.0%0.06%
+16.0%
Q3 2020$372,000
-6.1%
1,5000.0%0.05%
-12.3%
Q2 2020$396,000
+39.4%
1,5000.0%0.06%
+18.8%
Q1 2020$284,000
-13.7%
1,5000.0%0.05%
+6.7%
Q4 2019$329,000
+11.9%
1,5000.0%0.04%
+4.7%
Q3 2019$294,000
-6.1%
1,5000.0%0.04%
-8.5%
Q2 2019$313,000
+5.0%
1,5000.0%0.05%
+2.2%
Q1 2019$298,000
+37.3%
1,5000.0%0.05%
+17.9%
Q4 2018$217,000
-29.1%
1,5000.0%0.04%
-18.8%
Q3 2018$306,000
+37.8%
1,5000.0%0.05%
+26.3%
Q2 2018$222,000
-2.2%
1,5000.0%0.04%
-7.3%
Q1 2018$227,0001,5000.04%
Other shareholders
BIO-TECHNE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 275,000$18,719,25020.14%
Montanaro Asset Management Ltd 408,800$27,827,0164.90%
Sandhill Capital Partners LLC 613,061$41,731,0913.90%
Pembroke Management, LTD 365,611$24,887,1413.40%
DF DENT & CO INC 3,349,047$227,969,6483.34%
Brown Capital Management 3,158,004$214,965,3323.30%
Ownership Capital B.V. 1,786,273$121,591,6033.05%
STONE RUN CAPITAL, LLC 86,335$5,876,8232.88%
Jackson Square Partners, LLC 1,260,547$85,805,4342.87%
Summit Creek Advisors LLC 284,681$19,378,2362.64%
View complete list of BIO-TECHNE CORP shareholders